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Abstract 
Human papillomavirus (HPV) is a common sexually transmitted infection (STI) that has been etiologically 
linked to cervical cancer. Different types of samples can be used for cervical screening, including Pap test or 
biopsy and Liquid Based Cytology, visual inspection using acetic acid or Lugol’s iodine, and HPV testing. These 
methods are invasive. The use of urine as an alternative specimen may be more widely accepted since it is non-
invasive and the sample is readily available. The study aimed at detecting and genotyping HPV in urine from 
patients attending a sexually transmitted infections clinic in Nairobi County. It also aimed at assessing the factors 
associated with HPV infection. In this cross-sectional study, a structured ‘risk factor’ questionnaire was 
administered and HPV from urine specimen was genotyped using the L1 gene. Phylogenetic and molecular 
evolutionary analyses were conducted. Bivariate analysis and Pearson’s chi square (χ2) tests were used to 
determine the association between HPV infection and factors associated with HPV. A total of 222 adults (45 
males and 177 females) aged 18-49 years were recruited. The prevalence of HPV among males and females was 
22.2% (10/45) and 32.8% (58/177) respectively. The prevalence of high-risk types among males and females 
was 25% (1/4) and 27.5% (11/40) respectively. The high risk HPV genotypes detected among females were: 
HPV-16 (10%), -66 (7.5%), and -70 (7.5%) while low risk types were HPV 6 (27.5%), followed by -81 (25%), -
83 (10%), -11 (7.5%), and -54 (2.5%) respectively. The prevalence of low risk types among males and females 
was 75% (3/4) and 72.5% (29/40) respectively. The prevalent low-risk HPV type detected in males was HPV 
type 6 (75%) while HPV-58 (25%) was the only high risk type in males. History of sexually transmitted 
infections was significantly associated with HPV infection among females (P=0.002). There was also significant 
association between marital status among males (p=0.046), how often one had used the contraceptives among 
females (p=0.038) and HPV genotypes at bivariate level. The results indicate high HPV prevalence, high risk 
and low risk HPVs could be detected in urine from the two populations. Therefore; molecular testing of HPV on 
urine samples is a method that utilizes a non-invasive technique that may increase screening coverage as it is 
easy to obtain. 
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1. Introduction   
Human papillomavirus (HPV) is a common STI in the world. Up to 80% of sexually active people will be 
infected at sometime in their lives with approximately 10-20% developing persistent infection (Einstein et al., 
2009).  However, majority of genital HPV infections are transient and regress spontaneously within 1-2 years of 
initial infection (Monsonego et al., 2004). It is estimated by the World Health Organization (WHO) that 530,000 
new cases of cervical cancer and 270,000 deaths are reported yearly in the world, with 85% of these deaths 
occurring in developing countries (Formana et al., 2012). More than 128 genotypes have been characterized 
based on DNA sequence analysis (Zur Hausen, 2006; de Villiers et al., 2004). Furthermore, HPVs are classified 
as either cutaneous or mucosal types (International Agency for Research on Cancer, 2011). The cutaneous types 
are epidermitropic while mucosal types are highly epitheliotropic (Burd, 2003). Mucosal HPV types are further 
classified into high risk (HR) such as (HPV-16, -18, -31, -33, -34, -35,-39, -45, -51, -52, -56, -58, -59, -66, -68, -
69, -70, -73, -59 and -82) and low risk (LR) HPV types (6, 11, 42, 43 and 44) (Trottier & Burchell, 2009; 
Bouvard et al., 2008 ). LR HPV types, such as HPV 6 or 11 can cause benign or low-grade abnormalities of the 
cervix, anogenital warts and recurrent respiratory papillomatosis (RRP) (Munoz et al., 2003). HR-HPV types 
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such as 16 and 18 are implicated with squamous intraepithelial neoplasias (SILs) of the anogenital area, 
including cervical, vulvar, vaginal, penile, and anal and oropharyngeal cancers (Parkin &Bray, 2006; Watson et 
al., 2009; Gillison, 2008). Currently, different types of samples can be used for screening cervical cancer. These 
may include: conventional cervical cytology (Papanicolaou (Pap smear)) or biopsy and liquid based cytology 
(LBC), visual inspection using acetic acid or Lugol’s iodine (VIA-VILI), and HPV nucleic acid testing (NAT) 
(Tota et al., 2014). Pap smear screening is the gold standard that is based on detecting abnormal cellular changes 
of cervical cells or premalignant lesions in asymptomatic women. However, NAT method is more sensitive than 
conventional cytology as it can be used to detect oncogenic HPV types responsible for lesions with normal 
cytology or low-grade squamous intraepithelial lesions (LSIL) (Wang et al., 2013). Screening by this method has 
limitations. It is estimated that only 15-50% of patients with HPV infections are accurately identified by Pap 
smears (Meisels, 1983; Purola & Savia, 1977). Further, there is poor patient compliance as the efficacy of 
screening relies on repeated visits and obtaining samples is invasive and requires pelvic examination which is 
uncomfortable as well as it is time consuming for the health care provider (Reddy & Wasserman, 1997). 
Moreover, the success of Pap smear is hindered by women’s educational levels, misconceptions, prejudices and 
socio-cultural barriers in low resource settings. Due to these challenges, identification of the disease during late 
stage, leads to high rates of cervical cancer incidence and mortality (Sankaranarayanan et al., 2001; Cuzick et al., 
2008; Tornesello et al., 2014). Perhaps, using alternative screening tools can overcome these challenges and 
could improve screening coverage among populations from low resource settings. Several studies have showed 
that HPV DNA could be detected with high sensitivity on urine samples (Brinkman et al., 2002; Melchers et al., 
1989). Moreover, HPV DNA testing on urine samples is widely accepted because the sample is easily collected, 
non-invasive, and readily available especially for mass screening (Manhart et al., 2006). Urine samples have 
been used to detect HPV in pre-cancer and cancer women (Das et al., 1992). However, for asymptomatic 
infected men, there is no standard screening method as several sampling sites have been suggested for reliable 
detection of HPV in men (Melchers et al., 1989). In addition, HPV is readily transmitted from men (reservoir) to 
women and greatly affects the risk of disease in women (Buckley et al., 1981; Zunzunegui et al., 1986; Agarwal 
et al., 1993; Bosch et al., 1996; Castellsague et al., 2002). Male sexual behaviour affects rates of HPV infection 
and disease in female partners; hence an improved understanding of the infection in men is an important 
component of HPV-related cancer prevention. Thus we aimed at determining the prevalence and genotypes of 
HPV in urine from patients attending a STI clinic in Nairobi County. Furthermore, this study aimed at assessing 
the factors associated with HPV infection. 
 
2. Methods  
The study was a descriptive cross-sectional study that involved the collection of urine from individuals attending 
the Special Treatment Centre (STC) clinic between August 2013 and March 2014. Prior to the study, approval 
was granted by KEMRI National Review Board (SSC NO. 2442) and Nairobi County Department of Health 
Services. The clinic offers a range of STI care and treatment; provides free condoms, Voluntary and Counseling 
Testing unit (VCT), cervical screening, family planning and other related services. The study population 
comprised of Commercial Sex Workers (CSWs) and individuals aged between 18 and 49 years presenting with 
STI related symptoms in Nairobi County who consented to participate. A sample size of 222 was calculated as 
the representative of the population (both males and females). Patients attending the clinic were conveniently 
sampled to participate in the study. Potential participants were approached individually in the facility and those 
willing to participate, were invited for an interview by trained enumerators. Written informed consents were 
obtained to ensure that they understood everything about the purpose of the study.  Data regarding factors 
associated with HPV infection were collected using a structured questionnaire. After the collection of data, 
participants were requested to provide approximately 10ml mid-stream self collected urine samples that were 
collected in 15 ml sterile falcon tubes containing 0.8 ml boric acid. The collected urine samples were then 
transported to Kenya Medical Research Institute (KEMRI) in a cold chain and stored at -20°C till use.  
Each urine sample was initially subjected to centrifugation at 5,000 RPM for 10 minutes and the supernatant was 
discarded. The cell pellet was re-suspended in 0.5ml Phosphate Buffered Saline (PBS). Nucleic acid (HPV DNA) 
was extracted from the pellet using the QIAmp DNA Mini kit (QIAGEN, Valencia, CA) according to the 
manufacturer’s protocol. Briefly, 200 µL aliquot of urine sample was digested with 20µL of proteinase K, then 
lysed using 200µL lysis buffer, incubated at 56°C for 15 minutes.  DNA was eluted in 50 µL Rnase free water. 
The extracted DNA was stored at -20 0C until use. The DNA were amplified in a PCR targeting the L1 gene of 
HPV using the MY09/11 consensus primers for first round and GP5+/GP6+ modified primers for the second 
round of amplification (Michelle et al., 2011). For every PCR reaction, a negative control (H2O) and a positive 
control (in-house) was used as control The following amplification profile was used for primary PCR: 950C 
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initial activation for 30 seconds, 950C denaturation for 30 seconds, 480C annealing for 30 seconds, and 720C 
extension for 1 min for 40 cycles; followed by a 10 minutes final extension at 720C; and a hold step at 40C while 
for secondary PCR: 950C initial activation for 30 seconds, 950C denaturation for 30 seconds, 430C annealing for 
30 seconds, and 720C extension for 1 min for 40 cycles; followed by a 10 minutes final extension at 720C; and a 
hold step at 40C. All amplified products were separated by electrophoresis in a 2% agarose gel stained with 
ethidium bromide. 
All PCR products that had amplified for HPV DNA were purified using QIAquick Purification kit according to 
the manufacturer’s instructions; briefly, 5 volumes of buffer PB was added to 1 volume of PCR reaction and 
mixed. Followed by the addition of 10 microlitres of 3M Sodium acetate (PH 5.0) and mixed. In addition, 
washing was done by adding 750 µl buffer PE to the QIAquick column and then centrifuged for 30 seconds.  
Finally DNA was eluted by adding 50 microlitres of Rnase free water PH (7.0) and the column centrifuged at 
13000 RPM for1 minute. 
Amplicons were subjected to big dye terminator sequencing. Nucleotide sequences were edited and aligned 
using BioEdit sequence alignment editor software version 5.0.9. The newly sequenced (query sequences) were 
aligned along with reference sequences available in the gene bank. This was followed by CLUSTALW multiple 
sequence alignment. After some manual editing by stripping the ends the phylogenetic and molecular 
evolutionary analyses were conducted using MEGA6. Maximum parsimony test was used for phylogenetic 
reconstructions. The phylogenetic tree was constructed using MEGA 6. 
Descriptive statistics were used to give proportions and frequencies. Bivariate analysis, Pearson’s chi square (χ2) 
test was used to determine the association between HPV infection and factors associated with HPV. P < 0.05 was 
considered statistically significant. 
3. Results 
Demographic and behavioural characteristics of patients attending STC 
The demographic characteristics of patients are presented in (Table 1). A total of 222 adults aged 18-49 years 
with a mean age±SD of 32±SD=1.2 years were recruited. Forty five (20.3%) were males (mean age 34±SD=2.73 
years) and 177 (79.7%) were females (mean age 31±SD=1.33) (Table 1). The overall prevalence of HPV was 
22.2% and 32.8% among males and females respectively (Figure 1). Slightly less than half of males, 33.3% 
(15/45) were aged 40-49 years while 33.3% (59/177) females were aged 30-39 years. More than half of both 
males 66.7% (30/45) and females 54.2% (96/177) were married. Majority of males 48.9% (n=22) and females 
55.4% (n=98) had no children.  Most males 95.6% (43/45) and females 98.3% (174/177) were Christians. 
Majority of females 33.6% (56/177) had tertiary education. Less than half 33.3% (15/45) of males were formal 
employees while most females were self employed, 40.7% (72/177). Slightly half 82.2% (37/45) of males lived 
in permanent houses whereas more than half of females 71.2% (126/177) also lived in permanent houses. Most 
males 100% (n=45) and females 98.3% (n=174) were sexually active. Slightly half of males, 48.9% (n=22) had 
sex before18 years while majority of females 56.5% (n=100) were aged 19-24 years. Eighty six point seven 
percent (n=39) and 73.4% (n=130) males and females had two or more sex partners respectively. Most males 
35.6% (n=16) sometimes used condom during sex while most females 44.1% (n=78) never used condom during 
coitus. More than half males and females reported to have not used contraceptives at 95.6% (n=43) and 58.2% 
(n=103) respectively. Most males 82.2% (n=37) and females 98.3% (n=174) were not smoking. However, a 
large proportion 55.6% (n=25) of males were drinking alcohol while most females, 83.6% (n=148) were not 
taking alcohol. 
Distribution of HPV genotypes among patients attending STC in Nairobi 
The most frequently detected genotype was HPV-6 (75%), which is classified as low risk type while HPV-58 
(25%) was the only high-risk type detected among males. Among females, HPV types 16 (10%), 66 (7.5%), 70 
(7.5%), and 85 (2.5%) were the high-risk types that were detected. Among the Low risk types, HPV-6 (27.5%) 
was the most prevalent type detected followed by HPV-81 (25%), HPV-83 (10%), HPV-11 (7.5%) and 54 
(2.5%) respectively. The summary of both high and low risk HPV types are shown in (Table 2).  
Factors associated with HPV infection among patients attending STC in Nairobi 
Factors associated with HPV infection is presented in (Table 3). Age as a factor for HPV DNA positivity was not 
significantly associated with HPV infection. However, history of STIs and diseases was significantly associated 
with HPV infection among females only (χ2=9.894; p=0.002) at bivariate level. More than half 63.8% (37/58) of 
females reported to have had history of STIs whereas most males 90% (9/10) had history of STIs before. 
Cervical screening and HPV vaccination was also not significantly associated with HPV positivity among 
females. However, no risk factor was found to contribute independently to HPV infection on multivariate 
analyses. 
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HPV genotypes associated with factors for HPV infection among patients attending STC 
The prevalence of high-risk types among males and females was found to be 25% (1/4) and 27.5% (11/40) 
respectively. Further, the prevalence of low risk types among males and females was 75% (3/4) and 72.5% 
(29/40) respectively. How often one had used the contraceptives was significantly associated with HPV types 
among females (p=0.038). HPV genotypes in relation to factors for HPV DNA positivity are shown in (Table 4). 
HPV nucleotide accession numbers 
The nucleotide sequences that were determined in the present study were deposited in the Gene Bank and these 
are their accession numbers: [GenBank: KR674038-KR674081]. The accession numbers for the reference HPV 
nucleotide sequences are as follows: HPV-85 [GenBank:AF131950.1]; HPV-54 [GenBank:AF436129.1]; HPV-
16 [GenBank:AF548834.1]; HPV-83 [GenBank:AJ617544.1]; HPV-11 [GenBank:EF626589.1]; HPV-58 
[GenBank:JN383597.1]; HPV-70 [GenBank:JN617895.1]; HPV-6 [GenBank:JN617897.1]; HPV-66 
[GenBank:JN661519.1] and HPV-81 [GenBank:KM501530.1]. In figure 2, the phylogenetic tree is shown.  
 
4. Discussion  
Few studies have been conducted on the prevalence and genotyping of HPV in Sub-Saharan Africa, including 
Kenya.  Most of the data that are available are from HPV studies in women as data on infections in men are very 
limited. Most research has focused on HPV infection in women because of the association of HPV infection and 
cervical cancer using cervical smears but in men HPV is mostly asymptomatic. Therefore, to the best of our 
knowledge this is the first study in Kenya to report HPV infection and genotypes in urine. 
Among the 222 patients aged between 18-49 years who were enrolled, the crude prevalence was 22.2% (10/45) 
and 32.8% (58/177) in males and females respectively (OR at 95% CI; (0.272-1.266) χ2=1.878; p=0.171). The 
prevalence was high as well as low as compared to previous studies. There was an agreement in a study that was 
conducted among Japanese men who attended an STD clinic and the present study since they found an HPV 
prevalence rate of 22.1% in urine samples (Nakashima et al., 2014). While the present study found 22.2% HPV 
prevalence among the same population though the study populations and geographic locations was different. 
Smits et al., 2005 reported HPV prevalence in urine samples from 104 HIV infected and 115 uninfected men. 
The observed prevalence rates of HPV infection among HIV positive men was 39.4%. This was high as 
compared to the present study that recorded 22.2% prevalence among men. In the HIV positive men HPV 52 
was the most predominant genotype observed in 13 men (12.5%), followed by HPV types 18 (6.7%), 35 (5.8%), 
and 70 (4.8%). HPV 6 and 11 were only observed in two HIV-positive men and were absent in the HIV-negative 
group. In the present study, LR HPV types were found slightly more often than HR types in males. Among the 
LR types, HPV 6 (75%) was the most frequently detected among males while HPV 58 (25%) was the only HR 
type detected. In females, high risk types were the most frequently detected as compared to low risk types. The 
most prevalent HR HPV types detected among females were: HPV-16 (10%), 66 (7.5%), and 70 (7.5%) while 
HPV-85 (2.5%) was the least prevalent type detected. The most predominant LR HPV type detected in females 
was HPV type 6 (27.5%), followed by 81 (25%), 83 (10%), 11 (7.5%), and 54 (2.5%) respectively.  
The present study also found a high prevalence of HPV infection at 22.2% and 32.8% among males and females 
attending a STI clinic respectively as compared to a study by Bianchi et al., 2013 that reported a very low 
prevalence rate of 1.5% (13/870) of HPV infection among Italian adolescents, and found a significantly lower 
prevalence in boys 2/501 (0.4%) than in girls 11/369 (3.0%). In the two HPV DNA positive boys the infection 
was attributed to HPV-70 while in girls 63.6% (95%CI 33.6-87.2) of the 11 HPV-positive girls had a single 
infection and 4 (36.4%; 95% CI 12.8-66.4) were infected with two genotypes. A total of 8 different genotypes 
were detected among 15 infections identified in females: HPV-16 (4/15, 26.7%), HPV-70 (3/15, 20.0%), HPV-6 
and HPV-11 (2/15 each, 13.3%) and HPV-52, HPV-54, HPV-66 and HPV-87 (1/15 each, 6.7%). The only HPV 
positive girl among the 11-14-year age-group was infected with HPV-70. 
Paired 50 urine and 50 cervical samples from women patients study was compared to the present study. Thirty 
four percent (17/50) cases studied were positive for HPV DNA in the cervical samples, and 22% (11/50) cases 
were positive for HPV DNA in urine samples. This positivity is low as compared to the present study that 
determined 32.8% prevalence among females. This may be attributed to small sample size, different populations 
studied and different geographic distribution. When considering the viral type there was concordance in 7 of 9 
cases. HPV type 16 was detected in both cervical and urine samples. In 1 case, type 54 was detected in the 
cervical sample and type 77 in the urine sample; and in the remaining case, type 66 was detected in the cervical 
sample and type 68 in the urine sample (Alameda et al., 2007). 
In another study that consisted of 101 HIV-positive women recruited from the HIV Outpatient Clinic in New 
Orleans, La., who provided their urine samples and matching cervical swab samples. The overall prevalence of 
detection of any HPV DNA was 48% for the urine specimens and 58% for the cervical swab specimens. These 
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rates are higher as compared to the present study especially urine sampling that determined HPV prevalence rate 
at 32.8% among females. The differences in prevalence between these studies and the present study may be due 
to the different study populations that were evaluated. The prevalence rates of HPV positivity (32.8%) found in 
the present study also differ from those found in a study conducted by Sellors et al., 2000 with a population of 
women who were attending a colposcopy clinic. The overall prevalence of HPV of any type in the study was 
35% in urine specimens and 63% in cervical swab specimens respectively. The difference between the two 
studies can again be explained in part by the different populations examined (Brinkman et al., 2002). 
 
5. Conclusions  
High risk and low risk HPV can be detected in urine of sexually active individuals as it can be transported by 
urine, probably in the exfoliated infected HPV cells. The prevalence of HPV was also found to be high in both 
males and females attending STC despite small sample size of men who participated. Nucleic acid testing (NAT) 
using urine is a non-invasive and easier method to determine HPV infections among populations with poor 
gynaecologic attention. This is important for monitoring population prevalence and strategy for HPV vaccination 
especially among men and women. 
Future studies should focus on paired urine and cervical smears/endocervical swabs for women and for men 
penile/urethral swabs for comparison of HPV genotypes from different anatomical sites.  
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Table 1: Demographic and behavioural characteristics of patients attending STC 
 Gender 
 Male (n=45) Female (n=177)  
Variable  Frequency  Percent  Frequency  Percent  Total  
Age(years)      
18-24 7 15.6 44 24.9 51 
25-29 10 22.2 45 25.4 55 
30-39 13 28.9 59 33.3 72 
40-49 15 33.3 29 16.4 44 
Marital status      
Married 30 66.7 96 54.2 126 
Single  11 24.4 69 39   80 
Separated 4 8.9 11 6.2   15 
Widowed - - 1 0.6     1 
Religion      
Christians 43 95.6 174 98.3 217 
Muslims   2 4.4     3  1.7     5 
Education level      
No education - - 3 1.7   3 
Primary 15 33.3 60 33.9 75 
Secondary  15 33.3 58 32.8 73 
Tertiary  15 33.3 56 31.6 71 
Occupation      
Agricultural 
labourer 
2 4.4 3 1.7 5 
Formal employee 15 33.3 42 23.7 57 
Students   2 4.4 36 20.3 38 
Unemployed   4 8.9 14 7.9 18 
Self employed 15 33.3 72 40.7 87 
Other cadres   7 15.6 10 5.6 17 
Housing      
Temporary 3 6.7 32 18.1 35 
Semi-permanent 5 11.1 19 10.7 24 
Permanent 37 82.2 126 71.2 163 
Sexually active      
Yes  45 100 174 98.3 219 
No  - -     3   1.7   3 
Age at 1st sex      
Below 18 years 22 48.9 67 37.9 89 
19-24 years 20 44.4 100 56.5 120 
Above 25 years 3 6.7 10 5.6 13 
No. of sex partners      
None  - - 1 0.6 1 
One  6 13.3 46 26 52 
Two or more 39 86.7 130 73.4 169 
Condom use      
Never  14 31.1 78 44.1 92 
Rarely  8 17.8 17 9.6 25 
Sometimes  16 35.6 55 31.1 71 
Often  7 15.6 26 14.7 33 
Missing   - - 1 0.6 1 
Sex frequency/day      
None  4 8.9 25 14.1 29 
Once  23 51.1 106 59.9 129 
Twice  10 22.2 28 15.8 38 
More than twice 8 17.8 17   9.6 25 
Missing   1   0.6 1 
Genital hygiene      
Yes  38 84.4 150 84.7 188 
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No    7 15.6 26 14.7 33 
Missing  - - 1   0.6 1 
Parity       
None  22 48.9 98 55.4 120 
One  10 22.2 42 23.7 52 
Two  8 17.8 20 11.3 28 
Three  4 8.9 9 5.1 13 
>3 1 2.2 7 4 8 
Missing  - - 1 0.6 1 
Contraceptives use      
Yes  2 4.4 74 41.8 76 
No  43 95.6 103 58.2 146 
History of STIs      
Yes  29 64.4 83 46.9 112 
No  16 35.6 94 53.1 110 
Cervical screening      
Yes  - - 45 25.4 45 
No  - - 132 74.6 132 
HPV vaccination      
Yes  - - 2 1.1 2 
No  - - 175 98.9 175 
Smoking habits      
Yes  8 17.8 3 1.7   11 
No  37 82.2 174 98.3 211 
Alcohol uptake      
Yes  25 55.6 29 16.4 54 
No  20 44.4 148 83.6 168 
 
Table 2: Overall distributions of HPV types in males and females participants 
 Gender 
 Male Female 
HPV types Frequency Percent (%) Frequency Percent (%) 
  6 (LR) 3 75 11 27.5 
11(LR)     3  7.5 
16(HR)     4  10 
54(LR)     1  2.5 
58(HR) 1 25   -   - 
66(HR)     3  7.5 
70(HR)     3  7.5 
81(LR)     10 25  
83(LR)     4 10 
85(HR)     1   2.5 
Total 4 100 40 100 
 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.5, No.18, 2015 
 
111 
Table 3: Factors associated with HPV infection among patients attending STC 
HPV DNA status by gender 
 Male (n=45) Female (n=177) 
Variable positive      Negative  p-value Positive  Negative  p-value 
Age in yrs    0.927   0.807 
18-24 1(10%) 6(17.1%)  14(24.1%) 30(25.2%)  
25-29 2(20%) 8(22.9%)  14(24.1%) 31(26.1%)  
30-39 3(30%) 10(28.6%)  22(37.9%) 37(31.1%)  
40-49 4(40%) 11(31.4%)  8(13.8%) 21(17.6%)  
Marital status   0.515   0.22 
Married  7(70%) 23(65.7%)  27(46.6%) 69(58%)  
Single  3(30%) 8(22.9%)  27(46.6%) 42(35.3%)  
Separated  0(0%) 4(11.4%)  3(5.2%) 8(6.7%)  
Widowed  0(0%) 0(0%)  1(0.6%) 0(0%)  
Religion    0.334   0.983 
Christians  9(90%) 34(97.1%)  57(98.3%) 117(98.3%)  
Muslims  1(10%) 1(2.9%)  1(1.7%) 2(1.7%)  
Education level   0.598   0.127 
None 0(0%) 0(0%)  0(0%) 3(2.5%)  
Primary  2(20%) 13(37.1%)  14(24.1%) 46(38.7%)  
Secondary  4(40%) 11(31.4%)  23(39.7%) 35(29.4%)  
Tertiary  4(40%) 11(31.4%)  21(36.2%) 35(29.4%)  
Occupation    0.439   0.463 
Agric. Labourer 1(10%) 1(2.9%)  0(0%) 3(2.5%)  
Formal employee 1(10%) 14(40%)  11(19%) 31(26.1%)  
Students  1(10%) 3(8.6%)  6(10.3%) 8(6.7%)  
Unemployed 0(0%) 2(5.7%)  15(25.9%) 21(17.6%)  
Self employed  5(50%) 10(28.6%)  22(37.9%) 50(42%)  
Others  2(20%) 5(14.3%)  4(6.9%) 6(5%)  
Housing    0.411   0.720 
Temporary  0(0%) 3(8.6%)  12(20.7%) 20(16.8%)  
Semi-permanent 2(20%) 3(8.6%)  7(12.1%) 12(10.1%)  
Permanent  8(80%) 29(82.9%)  39(67.2%) 87(73.1%)  
Sexually active?   -   0.223 
Yes  10(100%) 35(100%)  58(100%) 116(97.5%)  
No  0(0%) 0(0%)  0(0%) 3(2.5%)  
Age at first sex   0.065   0.130 
<18 years 6(60%) 16(45.7%)  23(39.7%) 44(37%)  
19-24 years 2(20%) 18(51.4%)  29(29%) 71(59.7%)  
>25 years 2(20%) 1(2.9%)  6(60%) 4(3.4%)  
No. of sexual 
partners 
  0.725   0.573 
None 0(0%) 0(0%)  0(0%) 1(0.8%)  
One 1(10%) 5(14.3%)  13(28.3%) 33(27.7%)  
2 or more 9(90%) 30(85.7%)  45(34.6%) 85(71.4%)  
Condom use   0.866   0.099 
Never 4(40%) 10(28.6%)  18(31%) 60(50.8%)  
Rarely 2(20%) 6(17.1%)  7(12.1%) 10(8.5%)  
Sometimes 3(30%) 13(37.1%)  23(39.7%) 32(27.1%)  
Often 1(10%) 6(17.1%)  10(17.2%) 16(13.6%)  
Sex frequency in a 
day 
  0.58   0.492 
None  1(10%) 3(8.6%)  7(12.1%) 18(15.3%)  
Once  5(50%) 18(51.4%)  32(55.2%) 74(62.7%)  
Twice  1(10%) 9(25.7%)  12(20.7%) 16(13.6%)  
>twice 3(30%) 5(14.3%)  7(12.1%) 10(8.5%)  
Genital hygiene   0.660   0.246 
Yes  8(80%) 30(85.7%)  52(89.7%) 98(83.1%)  
No 2(20%) 5(14.3%)  6(10.3%) 20(16.9%)  
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Parity   0.098   0.634 
None  4(40%) 18(51.4%)  29(50%) 69(58%)  
One  4(40%) 6(17.1%)  18(31%) 24(20.2%)  
Two 0(0%) 8(22.9%)  7(12.1%) 13(10.9%)  
Three  1(10%) 3(8.6%)  2(3.4%) 7(5.9%)  
>three  1(10%) 0(0%)  2(3.4%) 5(4.2%)  
Contraceptive use   0.439   0.807 
Yes  0(0%) 2(5.7%)  25(43.1%) 49(41.2%)  
No  10(100%) 33(94.3%)  33(56.9%) 70(58.8%)  
History of STIs   0.056   0.002* 
Yes  9(90%) 20(57.1%)  37(63.8%) 46(38.7%)  
No  1(10%) 15(42.9%)  21(36.2%) 73(61.3%)  
Cervical screening   -   0.231 
Yes  0(0%) 0(0%)  18(31%) 27(22.7%)  
No  0(0%) 0(0%)  40(69%) 92(77.3%)  
HPV vaccination      0.602 
Yes  0(0%) 0(0%)    1(1.7%) 1(0.8%)  
No  10(100%) 35(100%)  57(98.3%) 118(99.2%)  
Smoking habits   0.835   0.983 
Yes  2(20%) 6(17.1%)  1(1.7%) 2(1.7%)  
No  8(80%) 29(82.9%)  57(98.3%) 117(98.3%)  
Alcohol uptake   0.297   0.130 
Yes  7(70%) 18(51.4%)  13(22.4%) 16(13.4%)  
No  3(30%) 17(48.6%)  45(77.6%) 103(86.5%)  
* Significant p<0.05 
Table 4: HPV types associated with factors for HPV DNA positivity among patients attending STC 
 HPV genotypes by gender 
 Male  Female 
Variable  High-risk Low-risk p-value High-risk Low-risk p-value 
Age in yrs   0.135   0.327 
18-24 0(0%) 0(0%) 
 
2(18.2%) 6(20.7%) 
 
25-29 1(100%) 0(0%) 
 
5(45.5%) 6(20.7%) 
 
30-39 0(0%) 1(33.3%) 
 
4(36.4%) 13(44.8%) 
 
40-49 0(0%) 2(66.7%) 
 
0(0%) 4(13.8%) 
 
Marital status   0.046*   0.796 
Married  0(0%) 3(100%) 
 
6(54.5%) 14(48.3%)  
Single  1(100%) 0(0%) 
 
5(45.5%) 14(48.3%)  
Separated  0(0%) 0(0%) 
 
0(0%) 1(3.4%)  
Widowed  0(0%) 0(0%) 
    
Religion    -   - 
Christians  1(100%) 3(100%)  11(100%) 29(100%)  
Muslims  0(0%) 0(0%)  0(0%) 0(0%)  
Education level   0.513   0.778 
None 0(0%) 0(0%)  0(0%) 0(0%)  
Primary  0(0%) 1(33.3%)  3(27.3%) 5(17.2%)  
Secondary  1(100%) 1(33.3%)  4(36.4%) 12(41.4%)  
Tertiary  0(0%) 1(33.3%)  4(36.4%) 12(41.4%)  
Occupation    0.505   0.609 
Agric. Labourer 0(0%) 0(0%)  0(0%) 0(0%)  
Formal employee 0(0%) 0(0%)  1(9.1%) 8(27.6%)  
Student 0(0%) 0(0%)  1(9.1%) 5(17.2%)  
Unemployed 0(0%) 0(0%)  3(27.3%) 6(20.7%)  
Self employed  1(100%) 2(66.7%)  5(45.5%) 9(31%)  
Other cadres 0(0%) 1(33.3%)  1(9.1%) 1(3.4%)  
Housing    0.505   0.973 
Temporary  0(0%) 0(0%)  2(18.2%) 6(20.7%)  
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Semi-permanent 0(0%) 1(33.3%)  1(9.1%) 3(10.3%)  
Permanent  1(100%) 2(66.7%)  8(72.7%) 20(69%)  
Sexually active?   -   - 
Yes  1(100%) 3(100%)  11(100%) 29(100%)  
No  0(0%) 0(0%)  0(0%) 0(0%)  
Age at first sex   0.505   0.910 
<18 years 1(100%) 2(66.7%)  5(45.5%) 11(37.9%)  
19-24 years 0(0%) 0(0%)  5(45.5%) 15(51.7%)  
>25 years 0(0%) 1(33.3%)  1(9.1%) 3(10.3%)  
No. of sexual partners   -   0.687 
None 0(0%) 0(0%)  0(0%) 0(0%)  
One 0(0%) 0(0%)  2(18.2%) 7(24.1%)  
2 or more 1(100%) 3(100%)  9(81.8%) 22(75.9%)  
Condom use   0.248   0.205 
Never 0(0%) 2(66.7%)  1(9.1%) 10(34.5%)  
Rarely 0(0%) 0(0%)  0(0%) 3(10.3%)  
Sometimes 1(100%) 1(33.3%)  7(63.6%) 11(37.9%)  
Often 0(0%) 0(0%)  3(27.3%) 5(17.2%)  
Sex frequency in a day   0.505   0.092 
None  0(0%) 0(0%)  1(9.1%) 2(6.9%)  
Once  1(100%) 2(66.7%)  6(54.5%) 16(55.2%)  
Twice  0(0%) 1(33.3%)  1(9.1%) 10(34.5%)  
>twice 0(0%) 0(0%)  3(27.3%) 1(3.4%)  
Genital hygiene   0.248   0.114 
Yes  1(100%) 1(33.3%)  9(81.8%) 28(96.6%)  
No 0(0%) 2(66.7%)  2(18.2%) 1(3.4%)  
Parity   0.135   0.933 
None  1(100%) 0(0%)  6(54.5%) 14(48.3%)  
One  0(0%) 2(66.7%)  4(36.4%) 10(34.5%)  
Two 0(0%) 0(0%)  1(9.1%) 3(10.3%)  
Three  0(0%) 0(0%)  0(0%) 1(3.4%)  
>3 0(0%) 1(33.3%)  0(0%) 1(3.4%)  
Contraceptives use   -   0.629 
Yes  0(0%) 0(0%)  4(36.4%) 13(44.8%)  
No  1(100%) 3(100%)  7(63.6%) 16(55.2%)  
If yes, how often      0.038* 
Regular  - -  2(66.7%) 12(100%)  
Sometimes  - -  1(33.3%) 0(0%)  
History of STIs   -   0.911 
Yes  1(100%) 3(100%)  7(63.6%) 19(65.5%)  
No  0(0%) 0(0%)  4(36.4%) 10(34.5%)  
Cervical screening   -   0.687 
Yes  - -  2(18.2%) 7(24.1%)  
No  - -  9(81.8%) 22(75.9%)  
HPV vaccination   -   0.100 
Yes  0(0%) 0(0%)  1(9.1%) 0(0%)  
No  1(100%) 3(100%)  10(90.9%) 29(100%)  
Smoking habits   0.505   - 
Yes  0(0%) 1(33.3%)  0(0%) 0(0%)  
No  1(100%) 2(66.7%)  10(100%) 29(100%)  
Alcohol uptake   0.505   0.687 
Yes  1(100%) 2(66.7%)  2(18.2%) 7(24.1%)  
No  0(0%) 1(33.7%)  9(81.8%) 22(75.9%)  
* Significant p<0.05 
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Figure 1: Prevalence of HPV according to gender 22.2% (10/45) among men and 32.8% (58/177) among 
women. 
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Figure 2: Phylogenetic analysis of L1 nucleotide sequences amplified by GP5+/GP6+ primers in HPV isolates 
from patients attending the STC clinic in Nairobi County. 
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